The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review
Open accessAbstract
Cardiovascular disease (CVD) is the main cause of death globally and responsible for the second highest number of deaths in Canada. Medical advancements in the treatment of CVD have led to patients living longer with CVD but often progressing to another condition called heart failure (HF). As a result, HF has emerged in the last decade as a major medical concern. Fortunately, various “traditional” pharmacotherapies for HF exist and have shown success in reducing HF-associated mortality. However, to augment the treatment of patients with CVD and/or HF, alternative pharmacotherapies using nutraceuticals have also shown promise in the prevention and treatment of these two conditions. One of these natural compounds considered to potentially help treat HF and CVD and prevent their development is resveratrol. Herein, we review the clinical findings of resveratrol’s ability to be used as an effective treatment to potentially help treat HF and CVD. This will allow us to gain a more fulsome appreciation for the effects of resveratrol in the health outcomes of specific patient populations who have various disorders that constitute CVD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Explaining the decrease in U.S. deaths from coronary disease, 1980–2000
Ford, E. S., Ajani, U. A., Croft, J. B., Critchley, J. A., Labarthe, D. R., Kottke, T. E., Giles, W. H., & Capewell, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmsa053935 · Cited by 2,757
Yancy, C. W., Lopatin, M., Stevenson, L. W., De Marco, T., & Fonarow, G. C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.09.022 · Cited by 927
Seferović, P. M., Petrie, M. C., Filippatos, G. S., Anker, S. D., Rosano, G., Bauersachs, J., Paulus, W. J., Komajda, M., Cosentino, F., de Boer, R. A., et al. (2018) · European Journal of Heart Failure · doi:10.1002/ejhf.1170 · Cited by 708
MacDonald, M. R., Petrie, M. C., Varyani, F., Ostergren, J., Michelson, E. L., Young, J. B., Solomon, S. D., Granger, C. B., Swedberg, K., Yusuf, S., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn153 · Cited by 694 · cited 1×
“In addition, the presence of diabetes increases the risk of myocardial infarction (MI) and stroke in HF patients [132].”
BackgroundEzekowitz, J. A., O'Meara, E., McDonald, M. A., Abrams, H., Chan, M., Ducharme, A., Giannetti, N., Grzeslo, A., Hamilton, P. G., Heckman, G. A., et al. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.08.022 · Cited by 676
Self-citationMahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475 · cited 15×
“Chen et al., 2015 [60] Double blind, randomized, placebo-controlled 60 adults with non-alcoholic fatty liver disease 300 mg of resveratrol (brand not provided) for 3 months Metabolic effects of resveratrol Decreased LDL-C and total cholesterol, glucose, or inflammatory cytokines.”
BackgroundMethodInfluentialHigh-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.11.015 · Cited by 319 · cited 4×
“Some clinical trials have found a decrease in plasma levels of inflammatory cytokines following resveratrol supplementation, including a decrease in the cytokines IL-6 [57,62,65,69,70], TNFα [57,60,62,69], high-sensitive CRP (hsCRP) or CRP [57,65,66], plasma interferon (IFN)-γ [58], and IL-8 [58] that could be linked…”
BackgroundInfluentialMéndez-del Villar, M., González-Ortiz, M., Martínez-Abundis, E., Pérez-Rubio, K. G., & Lizárraga-Valdez, R. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0082 · Cited by 246 · cited 1×
“, 2012 [63] Double blind, randomized, placebo-controlled 24 adults with metabolic syndromes 1500 mg of resveratrol daily for 90 days Cardiovascular and metabolic effects of resveratrol Decreases in total weight, BMI, fat mass, and waist circumference.”
BackgroundResveratrol blunts the positive effects of exercise training on cardiovascular health in aged men
Gliemann, L., Schmidt, J. F., Olesen, J., Biensø, R. S., Peronard, S. L., Grandjean, S. U., Mortensen, S. P., Nyberg, M., Bangsbo, J., Pilegaard, H., et al. (2013) · The Journal of Physiology · doi:10.1113/jphysiol.2013.258061 · Cited by 244
Candelario-Jalil, E., de Oliveira, A. C. P., Gräf, S., Bhatia, H. S., Hüll, M., Muñoz, E., & Fiebich, B. L. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-25 · Cited by 223
Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults
Wong, R. H. X., Berry, N. M., Coates, A. M., Buckley, J. D., Bryan, J., Kunz, I., & Howe, P. R. C. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e328362b9d6 · Cited by 162 · cited 7×
“Compared to the previously discussed inflammatory effects, RCT results measuring changes in endothelial function, often using flow mediated dilation (FMD) as an indicator, have been less variable.”
BackgroundResultInfluentialHeebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjær Poulsen, M., Stødkilde-Jørgensen, H., Møller, H. J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S., et al. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1107620 · Cited by 154 · cited 2×
“For example, multiple RCTs have shown no effect of resveratrol supplementation at various doses on lipid profile [44,45,51,52,56,62,68].”
BackgroundResistant Hypertension: A Review of Diagnosis and Management
Vongpatanasin, W. (2014) · JAMA · doi:10.1001/jama.2014.5180 · Cited by 146
Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I., Procopio, M., Pagano, G. F., Cassader, M., & Gambino, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.08.010 · Cited by 146 · cited 5×
“Some clinical trials have found a decrease in plasma levels of inflammatory cytokines following resveratrol supplementation, including a decrease in the cytokines IL-6 [57,62,65,69,70], TNFα [57,60,62,69], high-sensitive CRP (hsCRP) or CRP [57,65,66], plasma interferon (IFN)-γ [58], and IL-8 [58] that could be linked…”
BackgroundMethodResultInfluentialvan der Made, S. M., Plat, J., & Mensink, R. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118393 · Cited by 131
Olesen, J., Gliemann, L., Biensø, R., Schmidt, J., Hellsten, Y., & Pilegaard, H. (2014) · The Journal of Physiology · doi:10.1113/jphysiol.2013.270256 · Cited by 119 · cited 4×
“, 2014 [55] Randomized, double-blinded, placebo-controlled 43 healthy, physically inactive, elderly, men 250 mg of resveratrol (Fluxome Inc.”
BackgroundInfluentialSung, M. M., Das, S. K., Levasseur, J., Byrne, N. J., Fung, D., Kim, T. T., Masson, G., Boisvenue, J., Soltys, C.-L., Oudit, G. Y., et al. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.114.001677 · Cited by 102 · cited 2×
“Interestingly, numerous animal models of ischemic and non-ischemic HF have shown beneficial effects of resveratrol in HF that either prolongs survival [38], improves diastolic [38] or systolic function [150], reduces negative atrial and left ventricular remodeling [38,151,152], improves hemodynamics and cardiac energe…”
BackgroundSelf-citation
Cited by
Oxidative Stress in Cardiovascular Diseases
Dubois-Deruy, E., Peugnet, V., Turkieh, A., & Pinet, F. (2020) · Antioxidants · doi:10.3390/antiox9090864 · Cited by 646
Teka, T., Zhang, L., Ge, X., Li, Y., Han, L., & Yan, X. (2022) · Phytochemistry · doi:10.1016/j.phytochem.2022.113128 · Cited by 216
Metadata
- Authors
- Dyck, G. J. B., Raj, P., Zieroth, S., Dyck, J. R. B., & Ezekowitz, J. A.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-19
- Volume
- 20
- Issue
- 4
- Pages
- 904
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2915098654
- Cited by
- 200
- References
- 24
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.